FDA turnover fuels investor anxiety over rare drugs
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Yael Weiss says she receives daily investor emails questioning how recent FDA personnel changes will affect Mahzi Therapeutics’ rare‑disease drug approvals.
- Drug industry executives and an academic expert agree that the ouster of key FDA officials has generated significant anxiety and uncertainty for rare‑disease drug developers, especially regarding trial‑design flexibility.
- FDA turnover is prompting debate over how much flexibility the agency should allow in designing clinical trials for rare‑disease therapies.
Why it matters: Investors in rare‑disease biotech face heightened risk, while companies risk delayed approvals and funding gaps, potentially slowing patient access to life‑saving therapies and market valuations.
